Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Research Domains
  1. Home
  3. Research Domains

Related Concept Videos

  • Biomedical And Clinical Sciences
  • Oncology And Carcinogenesis
  • Predictive And Prognostic Markers
  • Use Of 70-gene Signature To Predict Prognosis Of Patients With Node-negative Breast Cancer: A Prospective Community-based Feasibility Study (raster).
  • Biomedical And Clinical Sciences
  • Oncology And Carcinogenesis
  • Predictive And Prognostic Markers
  • Use Of 70-gene Signature To Predict Prognosis Of Patients With Node-negative Breast Cancer: A Prospective Community-based Feasibility Study (raster).

    • Related Experiment Videos

    Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).

    Jolien M Bueno-de-Mesquita1, Wim H van Harten2, Valesca P Retel2

    • 1Department of Pathology, Divisions of Diagnostic Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands.

    The Lancet. Oncology
    |November 29, 2007

    View abstract on PubMed

    Summary
    This summary is machine-generated.

    A 70-gene breast cancer prognosis signature is feasible in community hospitals and can guide adjuvant treatment decisions. This signature may help spare patients from unnecessary chemotherapy side effects by improving treatment selection.

    Related Experiment Videos

    Area of Science:

    • Oncology
    • Genomics
    • Clinical Trials

    Background:

    • A 70-gene prognosis signature may enhance patient selection for adjuvant systemic treatment in node-negative breast cancer.
    • The MicroarRAy PrognoSTics in Breast CancER (RASTER) study aimed to assess the signature's implementation feasibility and impact on treatment decisions.

    Purpose of the Study:

    • To prospectively evaluate the feasibility of implementing a 70-gene prognosis signature in community settings.
    • To determine the effect of the 70-gene signature on adjuvant systemic treatment decisions when used with existing guidelines.

    Main Methods:

    • 812 women under 61 with primary breast carcinoma (T1-4N0M0) were enrolled between 2004-2006.
    • Microarray analysis assessed mRNA expression of 70 genes to classify prognosis as "good" or "poor."
    • Concordance between the signature and established guidelines (CBO, St Gallen, Nottingham Prognostic Index, Adjuvant! Online) was evaluated.

    Main Results:

    • The 70-gene signature identified 51% of 427 assessed patients as good prognosis and 49% as poor prognosis.
    • Significant discordance was observed between the signature and Dutch CBO guidelines (30%) and other assessed guidelines (37-39%).
    • Adjuvant treatment recommendations varied, with the signature potentially leading to more or fewer recommendations depending on the guideline combination.

    Conclusions:

    • The 70-gene prognosis signature is feasible for use in Dutch community hospitals.
    • Integrating the signature with guidelines altered adjuvant treatment recommendations, potentially sparing patients from adverse effects.
    • Further research is needed to confirm survival benefits and understand physician decision-making factors.